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2009 to Dec 2010) and diagnosis of bipolar I mixed disorder (ICD-9-CM: 296.6x) from 
MarketScan® claims databases, yielded 230 ASE, 2726 aripiprazole, 984 olanzap-
ine, 3056 quetiapine, and 1623 risperidone patients. PS were derived using logistic 
regression models for ASE and each AA with baseline demographic and clinical 
characteristics as covariates. PS, inverse probability treatment weight (IPTW: 1/
PS ASE; 1/ (1-PS) AA), and standard mortality ratio weight (SMR: 1 ASE; PS/ (1-PS) 
AA) distributions were evaluated. ASE-AA un-weighted, IPTW, and SMR baseline 
characteristics were compared using standardized differences, chi-squares, and 
t-tests. Results: Un-weighted asenapine patients had pre-index greater bipolar 
I episodes rates, psychiatric drug use, dyslipidemia and obesity (all comparators). 
PS distributions for asenapine-olanzapine overlapped to some degree while PS of 
asenapine and the other comparators overlapped little to not at all. Comparing IPTW 
baseline characteristics, asenapine more resembled the AA cohorts. Demographic 
imbalance increased between asenapine and each AA. IPTW improved clinical char-
acteristic balance for asenapine versus olanzapine and risperidone, but only slightly 
improved imbalance versus aripiprazole and quetiapine. However some clinical 
characteristics not previously balanced in the un-weighted analyses for asenapine 
versus each AA were now imbalanced. Applying SMR, AA cohorts more resembled 
the asenapine cohort and all baseline demographic and clinical characteristics 
were finally balanced. ConClusions: SMR, a less common PS method, resulted 
in balanced baseline characteristics. SMR should be considered when IPTW leaves 
imbalance and the cohort of primary interest differs significantly from the broader 
underlying population to which it’s being compared.
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objeCtives: A challenge in multi-centre Time and Motion (T&M) studies is perform-
ing inferential statistics, in light of hierarchical data. Our objective was to investigate 
two approaches to analyze the data. Methods: Task-based approach analysed 
tasks independently, mean times were summed, and 95% confidence intervals 
(CIs) were computed based on Variance Sum Law I (assuming time is independ-
ent among all tasks). Case-based approach involved imputation for missing time; 
all tasks per observation were summed, and a single time variable was analysed. 
Both approaches were applied to three countries participating in a multi-country 
T&M study comparing intravenous [IV] and subcutaneous [SC] administration 
processes. Absolute and relative differences in country means (case-based minus 
task-based) and the difference in CI range were computed using a random intercept 
model, to account for centre clustering. Results: Mean times were similar for both 
approaches. For IV process, absolute (relative) differences in time were -0.03min 
(-0.1%) in France, -0.77min (-2.3%) in Italy, and -0.07min (-0.3%) in Russia. For SC 
process, results were 0.30min (2.1%) in France, 0.90min (4.5%) in Italy, and 0.01min 
(0.1%) in Russia. The differences in CI range between both approaches were notice-
able: 0.51min (5%) in France, 25.04min (57%) in Italy, and 10.06min (46%) in Russia for 
IV and 4.38min (40%) in France, 0.88min (5%) in Italy, and 8.19min (56%) in Russia for 
SC. ConClusions: The choice of task-based or case-based approach did not impact 
mean process time; however, since task-based approach assumed independence of 
task times, it resulted in much narrower CI range. On the other hand, case-based 
approach eliminates the underestimation of variations, thus may therefore be a 
more optimal choice to analyse time outcomes for complex processes. With only a 
single time variable being analysed, it also allows pooling of data across countries, 
therefore providing more power to generate reliable CIs.
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objeCtives: In health technology assessment (HTA) decisions about reimburse-
ment of new health technologies are largely based on effectiveness estimates 
obtained from pre-prepared meta-analysis of evidence from randomised con-
trolled trials. However, there is not always a consensus amongst the decision-
makers about the inclusion criteria of studies into the meta-analysis. Therefore an 
approach that allows stakeholders to manipulate the content of the meta-analysis, 
thus facilitating a critical sensitivity analysis in real time during the decision-
making process, would be valuable from the point of view of the transparency of 
the HTA submissions. A Graphical-User-Interface (GUI) was designed to facilitate 
such a transparent decision-making process. Methods: The GUI was designed 
using freely available software packages which included WinBUGS for develop-
ment of meta-analysis and meta-regression models and R which was used to 
design GUI, to link data with statistical models in WinBUGS and to extract the 
results. R was also used to develop graphical tools for presentation of results (for-
est and bubble plots) and for visual assessment of publication bias (funnel plots). 
Software was designed for an illustrative example in rheumatoid arthritis where 
effectiveness of TNF-alpha inhibitors was measured on different scales (DAS-
28, HAQ, ACR, and EULAR). Results: R-based Transparent Interactive Decision 
Interrogator (R-TIDI) was developed, which is a user-friendly tool with “point and 
click” options that allows users to choose an outcome measure and run random-
effects or fixed-effects meta-analysis and meta-regression models. Users are not 
required to have knowledge of statistical software or programming skills since 
the use of WinBUGS and R is entirely “behind the scenes”. R-TIDI enables users to 
interactively include/exclude studies from the meta-analysis allowing for conduct-
ing sensitivity analyses in real time. ConClusions: R-TIDI is a useful tool for 
non-statistical decision-makers. It allows users to run sensitivity meta-analyses 
widely used in manufacturers’ submissions to date. Of the most recent 60 NICE 
TAs, analyses employing MAIC methodology have been presented in two submis-
sions and a STC analysis in a single HTA, all in the oncology setting. In all cases 
the review group identified limitations with the statistical methodology presented, 
although their use as exploratory analyses supporting results from conventional 
meta-analyses was highlighted in one submission. In particular the use of non-
randomised data from single treatment arms was highlighted as a potential weak-
ness of STC. ConClusions: In spite of the increasing published evidence base 
reporting on MAIC in a range of indications, both MAIC and STC have not been 
widely used in manufacturer’s submission to NICE. Assessment bodies critiquing 
the technology submissions remain to be convinced of the appropriateness of these 
novel techniques for the robust assessment of relative efficacy.
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objeCtives: Meta-analysis is often conducted in OpenBUGS. This software, like 
all BUGS projects, is based on MCMC simulations by using Gibbs sampling. One 
of the main issues in the use of Markov chains in a continuous space is the chain 
convergence. If the chain does not converge, transient states will be accounted for 
in our posterior distributions. Since these states are not bound to the empirical data 
but only with the chain’s starting point, the estimated parameters of the posterior 
distribution will be biased. To help assessing the convergence of MCMC chain, sev-
eral methods exist. Methods: Based on the literature, we run several simulation 
scenarios in order to test built-in OpenBUGS graphical methods and to assess the 
power of the “thin” approach, a fixed-step jumping-data method, for convergence. 
Then, we focus on the existing diagnoses, their supplementary assumptions and 
their associated computation costs. To help perform these diagnoses directly on 
BUGS objects, we present the R-package coda. Results: The use of jumping-data 
method leads to loss of power and a poorer estimation of posterior distribution 
even in case of high autocorrelation. Consequently, the use of the thin method is 
not recommended to obtain a quicker convergence and better posterior distribution 
estimation. We have also seen that although autocorrelogram and trace can be use-
ful to assess convergence, they can lead to misinterpretation in case of extremely 
low number of studies and conclude to convergence. Alternatively, using the Geweke 
diagnosis seems, in terms of computation cost and assumptions, recommended for 
two main advantages: it gives a measure of trust of being in a stationary process and 
very low computation cost. ConClusions: We presented methods to assess con-
vergence of MCMC chains and argued on their pros and cons. The Geweke diagnose 
was found to provide best trade-off between computational cost and interpretability.
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objeCtives: Treatment crossover refers to the situation in randomised controlled 
trials (RCTs) where patients randomised to the control group switch onto the experi-
mental treatment. This leads to biased estimates of treatment effects if not appro-
priately controlled for. Several crossover adjustment methods are available, but 
previous research has shown that the optimal adjustment method depends upon 
the characteristics of the trial. This study applies crossover adjustment methods 
to an RCT comparing trametinib to chemotherapy in patients with BRAF V600E/K 
mutation-positive advanced or metastatic melanoma (NCT01245062), and investi-
gates which adjustment method best fits this case study. Methods: The crossover 
adjustment methods applied include the Rank Preserving Structural Failure Time 
Model (RPSFTM), Iterative Parameter Estimation (IPE) algorithm, Inverse Probability 
of Censoring Weights (IPCW) and a two-stage accelerated failure time model estima-
tion procedure. Suitability of each method is compared by assessing the plausibil-
ity of the underlying assumptions of the models in this case study and analysing 
output and performance indicators associated with each method. Results: In the 
primary efficacy population (patients without history of brain metastases) 67.4% of 
chemotherapy patients switched onto trametinib. The intention to treat (ITT) hazard 
ratio (HR) for overall survival (OS) was 0.72 (95% CI 0.52-1.01). Point-estimates of 
the adjusted HRs produced by the most plausible applications of the RPSFTM, IPE, 
IPCW and two-stage methods ranged between 0.43 and 0.49, consistently favouring 
trametinib. Results were sensitive to the technique used to apply each method. Key 
issues included recensoring, the active nature of the comparator, and the choice of 
covariates included in the analyses. ConClusions: Each of the crossover adjust-
ment methods result in a lower HR than the ITT analysis. However, results are 
uncertain and sensitive to key assumptions. It is important to carefully analyse trial 
characteristics and model output when identifying which applications of adjust-
ment methods are most plausible.
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objeCtives: Asenapine (ASE), an oral Atypical Antipsychotic (AA), was initially used 
for more severe bipolar I mixed disorder. Different propensity score (PS) methods 
were investigated to achieve balanced baseline characteristics between ASE and 
four oral AA cohorts for eventual outcomes analyses. Methods: Adults with ≥ 1 
asenapine, aripiprazole, olanzapine, quetiapine, or risperidone prescription fill (Aug 
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and we show for different scenarios how close the estimates come. For selected 
treatment comparisons we present effect-sizes with confidence intervals. We apply 
also the Bayesian extension and discuss its advantages. ConClusions: Based on 
our research we give recommendations of when the Lumley-method should be best 
applied, and discuss limitations.1 Lumley T: Network meta-analysis for indirect 
treatment comparisons. Stat. Med. 2002; 21: 2313-2324.
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objeCtives: Evaluation and comparison of oral antidiabetic drugs (OAD) consump-
tion at state level are an important element at control of 2ndtype DM patients treat-
ment quality. The objective of the study is to determine the volumes and structure 
of OAD consumption in Ukraine and to compare it with consumption in the other 
countries. Methods: ATC/DDD-methodology with application of DDD/1000/day 
(DID). The evaluation is based on consumption volume, provided by “PharmXplorer/
Pharmstandard” analytical system of market research. Results: In year 2008, OAD 
consumption in Ukraine was 5.78 DID and increased to 11.13 DID in year 2013. In 
year 2011, OAD consumption was 54.28 DID in France, 44.58 - in Germany (S. Pichetti, 
C. Sermet, S. van der Erf, 2013), 33.25 - in Estonia, 29.87 - in Latvia (Baltic Statistics 
on Medicines 2010–2012), showing that OAD consumption in Ukraine was very low. 
Structure of OAD consumption in Ukraine shows that 98.95% of the total consump-
tion volume is distributed to 2 groups: sulfonylureas (73.84%) and biguanides (25%) 
and only 1,05% to gliptines, glitazones, glucosidases and glinides. The total share 
of preparations of sulfonylureas and biguanides group in the total consumption 
structure in France and Germany was 71.8% and 80.1% respectively of the total 
consumption OAD. In year 2013, OAD of the II generation - gliclazide (3.01 DID) and 
glibenclamide (2,09 DID) had the highest consumption level in sulfonylureas group, 
preparations of III generation - glimepiride (2,09 DID) had lesser consumption rate. 
Out of 61 OAD trade names (TN), presented in the pharmaceutical market of Ukraine, 
8 TNs took 89.78% of the total consumption volume. ConClusions: Very low rate 
of OAD consumption in Ukraine shows the necessity of its increase. Analysis of OAD 
consumption structure evidences the application of relatively cheap and long-used 
medical preparations for treatment of 2nd type DM, which is largely due to financial 
capacities of payers.
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objeCtives: In the context of uncertainty due to the lack of sound data, expert 
opinion is considered as a legitimate source of information for decision-makers. 
The use of experts’ opinion requires to quantifying their uncertainty about a specific 
event by eliciting a probability distribution of the event. The objectives of this study 
were to develop a web-based tool enabling users to remotely elicit the opinion of a 
group of geographically dispersed experts and to evaluate the measurement prop-
erties of this tool. Methods: The web-based tool allowed first to elicit univariate 
probability distributions separately from each expert and secondly to calculate an 
aggregated distribution. The elicitation method was the four-interval method that 
was judged to be more appropriate for non-statistician experts due to its clarity 
of use. As recommended to limit biases, the elicitation questionnaire included a 
training exercise and a graphical feedback so that the experts could validate their 
distributions. A pilot survey was conducted among all the French regional medical 
device vigilance correspondents (n= 24) about the risk of failure (%) of an implantable 
medical device. Results: Twenty-two correspondents (92%) completed the survey. 
An aggregated distribution was calculated from the elicited individual distributions 
and a beta distribution was fitted reflecting the group uncertainty about the risk of 
failure. Feasibility was judged in view of the users’ feedback and time to completion. 
Validity and reliability were assessed using data on comprehensiveness, internal 
coherence and test-retest reliability. ConClusions: The proposed web-based tool 
was feasible, valid and reliable. It should be useful in making expert elicitation 
easier and more practical.
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objeCtives: The main objective of the study is to promote awareness and assess 
the knowledge of adolescents on medication use, importance of balanced diet and 
physical activity. Methods: The study was conducted among the adolescents 
aged from16-18 years in Regions of Guntur. The volunteers are allowed to fill their 
informed consent to be a part of the study. The questionnaire was distributed to all 
the volunteers included in the study, which includes questions on their medica-
tion taking behaviour, dietary habits and physical activity. The response was then 
analyzed to assess the knowledge on medication use, balanced diet and physical 
activity. Results: Among the 165 individuals on assessment of their medication 
taking behavior78% of them do not follow their prescription, 61% of the individuals 
do not have any idea on their medication use and a majority of 74% are not aware 
of the unwanted effects caused by the medication. On assessment of their dietary 
habits and physical activity, 62% of the individuals include meal rich in fat, 42% 
of the individuals skip their breakfast every day and 41% of them will not include 
leafy vegetables as part of their regular meal. 65% of individuals do not perform a 
regular physical activity ConClusions: It is the responsibility of the pharmacist 
in a user-friendly environment during a decision-making setting avoiding disad-
vantages of pre-prepared analyses.
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objeCtives: HTA bodies increasingly require accurate survival estimates in order to 
provide reliable recommendations. It is argued that access to individual patient data 
(IPD) can improve their accuracy. This paper aims to assess to what degree extract-
ing IPD from published Kaplan-Meier curves helps improve extrapolated survival 
estimates. Some methods currently used for HTA submissions fit a survival curve 
directly to a published Kaplan-Meier curve, but does this lack accuracy? Methods: 
Two methods used to extract the IPD from Kaplan-Meier curves reviewed in this 
paper are by Guyot et al (Guyot, Ades, Ouwens, & Welton, 2012) and Hoyle and 
Henley (Hoyle & Henley, 2011) which were compared against the outcomes of the 
standard ‘least squares’ method. Comparisons were made for two situations: 1) 
when numbers at risk are available at different time points throughout the Kaplan-
Meier curve and 2) when numbers at risk are only available at the start. Results: 
The three methods resulted in the long-normal distribution showing the best fit, 
with all containing the true mean and median within their confidence intervals. 
However, the Hoyle and Henley method estimates a mean marginally closer to the 
true mean than the other methods in both situations. When many numbers at risk 
are provided, the Hoyle and Henley method gives narrower confidence intervals. 
Both extraction methods slightly outperformed the least squares method. The three 
methods give median estimates and resulting confidence intervals which are statis-
tically equivalent to that of the IPD, except for the Guyot method when numbers at 
risk are not available. ConClusions: In conclusion, extraction methods can give 
marginally better results than the Least Squares method. However, these results 
may not be applicable to other examples. In addition, the extra time taken to run 
extraction methods could be too large to account for the small improvement in 
accuracy of results.
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objeCtives: A frequent challenge in Network Meta-Analysis (NMA) arises from the 
fact that several interventions may belong to the same class and be given at multiple 
doses. Models have been proposed for NMA accounting for dose-response, but these 
models do not also consider class effects at the same time, which are important 
from a decision making perspective. We aim to develop a framework that extends 
dose-response NMA methods to account for dose and class effects simultaneously, 
and explore the ability of these models to explain heterogeneity, improve model fit 
and increase precision of the estimated treatment effects. Methods: Using clini-
cal trial data of treatments for acute migraine obtained from Cochrane reviews, we 
developed multi-level NMA models to simultaneously account for dose-response 
and class-effects, in particular defining a ‘dose’, ‘treatment’ and ‘class’ hierarchy 
within the NMA models. We explored a non-parametric “random walk” model con-
strained to be monotonically increasing with dose. Multi-level NMA models were 
compared to 1-level (standard) NMA models where interventions were ‘lumped’ at 
each level separately. Results: The model that explicitly included monotonic dose-
response and class effects showed the best fit and least heterogeneity, and produced 
more precise measures of treatment effect than all 1-level models. NMA models that 
made less plausible assumptions around dose-response had poorer fit than models 
with monotonic dose-response. ConClusions: We have developed a framework 
for simultaneously estimating treatment effects at the ‘dose’, ‘treatment’ and class 
level within the same NMA model. The framework can help decision makers iden-
tify the most appropriate class, drug, and dose, however, results of dose-response 
models are not straightforward to interpret or implement from a decision making 
perspective. Careful consideration should be given to dose-response and similarity 
of interventions when conducting NMA.
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objeCtives: In recent years we have seen a growth in the use of network meta-
analysis as part of the evidence base for Health Technology Assessments, with the 
Lumley method, published in 20021being a key reference when considering both 
indirect and direct comparisons. Unfortunately the program-code included in the 
manuscript cannot easily be run, and the given examples cannot be replicated, 
even with corrected code. To give practitioners helpful insight into the method, 
we start from individual patient data of head to head trials and show how from 
subsequent data-aggregation the Lumley-model (a random-effects model) can be 
derived. Methods: We give more details than in the article of how the proposed 
variance function aggregates study-heterogeneities and of how effect-sizes and 
confidence intervals can be derived from the parameter- and variance-estimates. 
We discuss why dependencies coming from the network-structure should be incor-
porated into confidence-interval calculations and of how the model can be extended 
with an in the article suggested Bayesian approach for modeling the random-effects 
parameters. Results: We include an example of how the Lumley-method can be 
applied in practice. We present based on the program-example in the article a cor-
rected R-version and a translation into SAS. For both we show how aggregated 
study-data should be structured and dummy-coded before running the program. 
The Lumley-method was applied to simulated data with known model-parameters 
